Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Nov 8;17(1):142.
doi: 10.1186/s12933-018-0785-x.

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity

Mengdie Luo  1 , Ziyu Zhang  1 , Yani Peng  2 , Shuai Wang  1 , Daoquan Peng  3
Affiliations
Comparative Study

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity

Mengdie Luo et al. Cardiovasc Diabetol. .

Abstract

Background: It is well known that angiopoietin-like protein 8 (ANGPTL8) exerts its effects on lipid metabolism through the inhibition of lipoprotein lipase and subsequent elevation of plasma triglyceride. However, it is not clear whether ANGPTL8 could affect lipid metabolism via other pathways. The study was aimed to investigate the effects of ANGPTL8 on the function of high-density lipoprotein (HDL), which plays a protective role in atherosclerosis progression.

Methods: Two hundred and ten subjects were recruited. Plasma ANGPTL8 was measured by enzyme-linked immunosorbent assays. Cholesterol efflux capacity was chosen as the biomarker of HDL function and measured via H3-cholesterol loading THP-1 cell models.

Results: ANGPTL8 exhibited no significant difference between CAD group and nonCAD group, but ANGPTL8 in DM group was significantly higher than that in the nonDM group [568.3 (406.2-836.8) vs 458.2 (356.8-755.6), P = 0.023]. Compared to controls, subjects in CAD group and DM group exhibited significantly lower cholesterol efflux capacity [CAD: 14.58 ± 2.06 vs 12.51 ± 2.83%, P < 0.0001; DM: 13.62 ± 2.57 vs 12.34 ± 3.16%, P = 0.0099]. ANGPTL8 was inversely correlated with cholesterol efflux capacity (r = - 0.188, P < 0.01). Regression analysis revealed that plasma ANGPTL8 was an independent contributor to cholesterol efflux capacity (standardized β = - 0.143, P = 0.023).

Conclusion: ANGPTL8 presents a negative effect on HDL-mediated cholesterol efflux capacity.

Keywords: ANGPTL8; Cholesterol efflux capacity; Coronary artery disease; Diabetes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
ANGPTL8 from nonDM (n = 173) and DM (n = 37) patients. Data are expressed as median ± interquartile range. DM indicates diabetes mellitus. *P < 0.05
Fig. 2
Fig. 2
ANGPTL8 from low triglyceride group (n = 139) and high triglyceride group (n = 71) patients. Data are expressed as median ± interquartile range. TG indicates triglyceride. *P < 0.05
Fig. 3
Fig. 3
Cholesterol efflux capacity in nonCAD (n = 90) and CAD (n = 120) patients. Data are expressed as mean ± SD. CAD indicates coronary artery disease. ****P < 0.0001
Fig. 4
Fig. 4
Cholesterol efflux capacity in nonDM (n = 173) and DM (n = 37) patients. DM indicates diabetes mellitus. Data are expressed as mean ± SD. **P < 0.01
Fig. 5
Fig. 5
The correlation between plasma ANGPTL8 (log-transformed) and cholesterol efflux capacity in all the subjects
See this image and copyright information in PMC

References

    1. Emerging Risk Factors C. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000. doi: 10.1001/jama.2009.1619. - DOI - PMC - PubMed
    1. Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013;128(14):1504–1512. doi: 10.1161/CIRCULATIONAHA.113.002670. - DOI - PMC - PubMed
    1. Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267. doi: 10.1056/NEJMoa1107579. - DOI - PubMed
    1. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379. doi: 10.1136/bmj.g4379. - DOI - PMC - PubMed
    1. Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. Eur Heart J. 2014;35(29):1917–1924. doi: 10.1093/eurheartj/ehu208. - DOI - PubMed

Publication types